Corcept Therapeutics Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.corcept.com

Earnings Score
Moat Score

Market Cap $6.16B
PE 44
Debt $NaN
Cash $137.29M
EV $NaN
FCF $142.60M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$140.49M
EBIT	$166.34M
ROE	22%
ROA	21%
FCF	$142.60M
Equity	$638.84M
Growth Stability	97%
PE	43.83
PEG	18.5
PB	9.64
P/FCF	43.18
P/S	9.8
Price/Cash	0.02
Net Margins	22%
Gross Margins	98%
Op. Margins	26%
Earnings CAGR	30%
Sales Growth YoY	48%
Sales Growth QoQ	11%
Sales CAGR	28%
FCF CAGR	35%
Equity CAGR	50%
Earnings Stability	0.38
Earnings Growth YoY	50%

Earnings Growth QoQ	33%
Earnings CAGR 5Y	2%
Sales CAGR 5Y	13%
FCF CAGR 5Y	-4%
Equity CAGR 5Y	5%
Earnings CAGR 3Y	20%
Sales CAGR 3Y	20%
FCF CAGR 3Y	-7%
Equity CAGR 3Y	16%
Market Cap	$6.16B
Revenue	$628.56M
Assets	$784.26M
Cash	$137.29M
Shares Outstanding	103.09M
Earnings Score	41%
Moat Score	96%
Working Capital	340.76M
Current Ratio	3.7
Gross Profit	$618.75M
Shares Growth 3y	-2%
Equity Growth QoQ	7%
Equity Growth YoY	38%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

SEC Filings

Direct access to Corcept Therapeutics Inc (CORT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Corcept Therapeutics Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Corcept Therapeutics Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 30%

Stability 38%

loading chart...

Corcept Therapeutics Inc Discounted Cash Flow

Fully customizable DCF calculator online for Corcept Therapeutics Inc.

Years

Calculation mode

= $16B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$143M	$192M	$258M	$347M	$468M	$629M	$847M	$1.1B	$1.5B	$2.1B	$2.8B	$28B
DCF		$174M	$213M	$261M	$319M	$391M	$478M	$585M	$715M	$875M	$1.1B	$11B
Value	$16B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-118%	-13%	10%	81%	30%	31%	30%	31%	25%	22%	22%
ROA	-	-7%	15%	24%	29%	28%	23%	29%	20%	20%	21%
ROE	-	-35%	20%	68%	27%	25%	20%	30%	20%	21%	22%

Good Net Margins (22.17%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	19.26	0.81	0	-	-	-	-	-	-	-
Debt over Equity	-16.06	3.24	0.35	0	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	100%	100%	100%	100%	97%	99%	97%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (97%)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	89%	62%	96%	58%	22%	15%	3%	10%	20%	13%
Earnings YoY growth	-	-80%	-227%	1K%	-42%	25%	13%	6%	-10%	4%	2%
Equity YoY growth	-	-646%	124%	362%	44%	35%	41%	-28%	34%	1%	5%
FCF YoY growth	-	-111%	485%	233%	91%	17%	12%	11%	-28%	6%	-4%